This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.


Self-injection best practices: Designing family planning programs that work

June 18, 2018 by PATH

Research in Uganda and elsewhere shows that women can self-administer DMPA-SC safely and effectively, that they like doing so, and that self-injection helps support continued use of injectable contraception.

A woman self-injects the contraceptive, subcutaneous DMPA (DMPA-SC). PATH/Gabe Bienczycki

A woman self-injects the contraceptive DMPA-SC (brand name Sayana Press). Photo: PATH/Gabe Bienczycki

As the Uganda Ministry of Health plans for national rollout of this new option for women, PATH’s DMPA-SC Self-injection Best Practices initiative is gathering information about how the practice can be designed and implemented at a broader scale. The team in Uganda has applied user-centered design techniques to develop, implement, and evaluate self-injection program models across delivery channels: public-sector facilities, community-based distribution, private-sector outlets, and safe spaces for young women and adolescent girls. As of late 2018, program data showed that more than 7,000 women were using self-injection contraception across four districts.

As PATH evaluates these programs, we are regularly sharing insights and lessons learned. If you are planning a self-injection program in your country please feel free to email For more information, see the resources listed below, visit, orsign up for our newsletter.

*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate

Sayana Press is a registered trademark of Pfizer Inc.

“It saves time to inject at home, and it’s private. Another reason is you get courage. I used to fear the needle so much.”
— Self-injection client, Uganda


Read More